Biocon secures global settlement with Genentech for Pebrilzo launch EP News Bureau Oct 14, 2026 The agreement sets licensed launch dates for Biocon’s pertuzumab biosimilar in the EU, UK, US and other markets
Biocon receives EMA CHMP approval for Pertuzumab biosimilar EP News Bureau Sep 21, 2026 Biocon Biologics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)…
Alkem launches Pertuza in India to treat HER2-positive breast cancer EP News Bureau Sep 23, 2025 Alkem Laboratories has announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment…
